Hybridon/Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Medtronic makes a $4 mil. equity investment in the Worcester, Massachusetts-based firm as part of a research collaboration pact to develop antisense oligonucleotide compounds and delivery systems for the treatment of Alzheimer's disease. Under the terms of the deal, Hybridon will develop the compounds and perform initial studies. Depending on the outcome, the compounds could be adapted for use with Medtronic's SynchroMed implantable drug infusion system.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.